STOCK TITAN

Outset Medical, Inc. - OM STOCK NEWS

Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.

Outset Medical, Inc. (OM) drives innovation in dialysis care through its groundbreaking Tablo Hemodialysis System. This page serves as the definitive source for verified news and press releases about the company’s advancements in medical technology, financial performance, and strategic initiatives.

Access real-time updates on product milestones, regulatory developments, and clinical partnerships that shape OM’s position in the healthcare sector. Investors and healthcare professionals will find comprehensive coverage of earnings reports, FDA clearances, and technology adoption trends across hospitals and home care settings.

Our curated news collection features:

• Product Innovations: Latest enhancements to the Tablo system’s integrated dialysis solutions
• Financial Updates: Quarterly earnings and strategic investment announcements
• Clinical Partnerships: Collaborations improving renal care delivery models
• Regulatory Milestones: FDA clearances and compliance developments

Bookmark this page for streamlined access to OM’s evolving role in transforming dialysis through technology that prioritizes patient outcomes and operational efficiency.

Rhea-AI Summary

Outset Medical, Inc. (Nasdaq: OM) will release its second-quarter 2021 financial results on August 5, 2021, after market close. CEO Leslie Trigg and Interim CFO Nabeel Ahmed will host a conference call at 2:00 PM PT (5:00 PM ET) on the same day to discuss the results. Outset Medical is known for its innovative Tablo Hemodialysis System, which simplifies dialysis by integrating water purification and on-demand dialysate production, offering a portable solution for patients and healthcare providers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
conferences earnings
-
Rhea-AI Summary

Outset Medical (Nasdaq: OM) announces the departure of CFO Rebecca Chambers effective July 16, 2021, with Nabeel Ahmed stepping in as Interim CFO. The company predicts Q2 2021 net revenue between $24.5M to $25.0M, marking a remarkable growth of 109% to 113% year-over-year. Leslie Trigg, CEO, expresses gratitude towards Chambers for her contributions and confidence in Ahmed’s capabilities, given his extensive finance experience. Outset’s technology aims to simplify dialysis, enhancing patient care and operational efficiency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.86%
Tags
management
-
Rhea-AI Summary

Outset Medical, Inc. (Nasdaq: OM) has appointed Jean-Olivier Racine as Chief Technology Officer to lead advancements in its dialysis technology. Racine brings over two decades of experience, including roles at Amazon Web Services and expertise in health data services. He aims to enhance patient care and operational efficiency utilizing data-driven innovation. Outset’s FDA-cleared Tablo Hemodialysis System, known for its two-way wireless data transmission, allows real-time data sharing, aiding in analytics and service improvements. Racine's focus will support the unique capabilities of Tablo in transforming dialysis care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none
Rhea-AI Summary

Strive Health, a leader in value-based kidney care, and Outset Medical, Inc. (Nasdaq: OM), a dialysis innovator, have partnered to enhance kidney care. Strive aims to reduce hospitalizations for kidney disease patients using Outset's Tablo Hemodialysis System for home dialysis. The collaboration focuses on delivering high-quality patient care and integrating predictive analytics. Strive recently launched a new dialysis facility in Owensboro, KY, emphasizing holistic kidney management. This partnership aims to improve patient experience and accessibility to home dialysis services.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
none
-
Rhea-AI Summary

Satellite Healthcare and Outset Medical (Nasdaq: OM) announced a multi-year sales agreement to enhance home hemodialysis adoption across Satellite Healthcare's dialysis centers. The agreement involves the purchase of Tablo systems for home use and collaboration on educational initiatives to increase patient awareness. Satellite Healthcare aims to lead in at-home dialysis treatment, serving over 8,000 patients annually. Factors such as Medicare Advantage eligibility and increased telehealth usage are expected to drive growth in home dialysis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
-
Rhea-AI Summary

Outset Medical, Inc. (Nasdaq: OM), a medical technology innovator, announced its management's participation in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 7:30am PT / 10:30am ET. The event will be available via live and archived webcast on Outset's investors page. Outset's flagship product, the Tablo Hemodialysis System, offers a groundbreaking solution to streamline dialysis delivery, ensuring it can be provided anywhere and anytime, significantly enhancing patient care and reducing costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
conferences
Rhea-AI Summary

Outset Medical, Inc. (Nasdaq: OM) appoints Katie Szyman to its board of directors. With over 30 years of experience, Szyman has a proven track record in global medtech, significantly growing businesses at Edwards Lifesciences and Medtronic. As VP at Edwards, she increased critical care revenue by nearly 50% to $800M in six years. Szyman aims to help Outset accelerate its growth and transformation in dialysis care delivery. Outset’s innovative Tablo™ Hemodialysis System simplifies dialysis, making it accessible in various settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
management
-
Rhea-AI Summary

Outset Medical (Nasdaq:OM) has joined the Moving Health Home coalition, aimed at transforming home healthcare by influencing policy changes. This initiative highlights the importance of home-based care, especially post-COVID-19, allowing patients to manage chronic diseases at home. Outset's Tablo Hemodialysis System offers a compact, user-friendly solution for dialysis, enabling patients to reclaim their autonomy. The coalition's goal is to advocate for legislative support to enhance home healthcare access, aligning with Outset's mission to improve patient outcomes and reduce healthcare costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
none
-
Rhea-AI Summary

Outset Medical, Inc. (OM) reported a significant first quarter in 2021 with net revenues of $22.9 million, up 219% from the prior year. The Company achieved a gross margin of 1.3%, improving from a gross loss of (49.6%) in Q1 2020. Operating expenses rose to $30.0 million, resulting in a net loss of ($30.0 million) or ($0.70) per share. Positive news includes strong demand for its Tablo system, leading to an updated revenue guidance of $92 million to $97 million for 2021, reflecting an 84% to 94% growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.07%
Tags
Rhea-AI Summary

Outset Medical, Inc. (Nasdaq: OM) will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 11:45am PT / 2:45pm ET. The event aims to discuss the company’s innovative dialysis technology, the Tablo Hemodialysis System, which simplifies dialysis treatment and enhances patient experience. A live and archived webcast will be available on Outset's website. This system allows for greater accessibility and efficiency in dialysis care, operating from hospital to home.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
conferences
Outset Medical, Inc.

Nasdaq:OM

OM Rankings

OM Stock Data

195.12M
17.57M
0.45%
18.84%
20.84%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
SAN JOSE